Medicure Inc.
1200 Waverley Street
Suite 4
Winnipeg
Manitoba
R3T 0P4
Canada
Tel: 204-487-7412 or 888-435-2220
Fax: 204-488-9823
Website: http://www.medicureinc.com/
Email: info@medicureinc.com
230 articles about Medicure Inc.
-
Medicure Reports Financial Results for Quarter Ended June 30, 2020
8/11/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020.
-
Medicure Q2 2020 Results and Conference Call Dates
8/5/2020
Medicure Inc., a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020.
-
Medicure Announces Normal Course Issuer Bid
6/29/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").
-
Medicure Announces Positive Results for AGGRASTAT in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation
6/29/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.
-
Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG (Pitavastatin) Tablets
6/25/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.
-
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
6/15/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial.
-
Medicure Reports Financial Results for Quarter Ended March 31, 2020
5/12/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2020.
-
Medicure Q1 2020 results and conference call dates
5/6/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended March 31, 2020 on Tuesday, May 12, 2020.
-
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019
4/15/2020
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter and year ended December 31, 2019.
-
Early Warning News Release - Dr. Albert D. Friesen Holdings in Medicure Inc.
12/31/2019
The Issuer's head office address and Dr. Friesen's business address is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.
-
Medicure Announces Preliminary Results of Substantial Issuer Bid
12/20/2019
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, announced today the preliminary results of its substantial issuer bid (the "Offer") to repurchase for cancellation up to 4.0 million of its common shares (the "Common Shares") at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash.
-
Medicure Announces the Completion of Shortened AGGRASTAT Versus Integrilin in Percutaneous Coronary Intervention (SAVI-PCI) Study
12/17/2019
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT® (tirofiban hydrochloride) injection versus Integrilin® (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.
-
Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)
12/12/2019
The study enrolled 120 patients. Medicure expects to release top-line data in Q1 of 2020.
-
Medicure Announces Settlement of Holdback Dispute from Apicore Sale
12/5/2019
Medicure Inc., a cardiovascular pharmaceutical company, announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement.
-
Medicure Reports Financial Results for Quarter Ended September 30, 2019
11/26/2019
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019.
-
Medicure Q3 2019 Results and Conference Call Dates
11/19/2019
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2019 on Tuesday, November 26, 2019.
-
Medicure Announces Intention to Commence Substantial Issuer Bid
11/4/2019
Medicure Inc., a cardiovascular pharmaceutical company, announced its intention to commence a substantial issuer bid pursuant to which the Company will offer to purchase up to 4.0 million of its common shares for cancellation at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash.
-
Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate
10/15/2019
Medicure Inc. is pleased to announce the primary results of the late-breaking SMILETM-Heart Failure Clinical Trial which was presented at the recent Heart Failure Society of America conference in Philadelphia, PA by Dr. William T. Abraham, the SMILE-HF national principal investigator.
-
Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force
10/3/2019
Medicure Inc. is pleased to announce that it has reached a preferred pricing agreement with the AIDS Drug Assistance Program Crisis Task Force for ZYPITAMAGTM tablets.
-
Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™
9/30/2019
Medicure Inc., a cardiovascular pharmaceutical company, is pleased to announce that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAGTM tablets, from Cadila Healthcare Ltd., India for US and Canadian markets.